Why should serum protein electrophoresis be ordered to evaluate for a monoclonal protein in a patient with focal peripheral neuropathy presenting as toe pain?

Why Order Serum Protein Electrophoresis for Peripheral Neuropathy?

Serum protein electrophoresis (SPEP) with immunofixation should be ordered because monoclonal gammopathies occur in approximately 10% of patients with otherwise unexplained peripheral neuropathy—a rate significantly higher than in the general population—and identifying these paraproteins is critical for detecting potentially treatable or life-threatening conditions like POEMS syndrome, AL amyloidosis, or underlying hematologic malignancies. 1

The Evidence-Based Rationale

High Diagnostic Yield in Neuropathy Workup

The American Academy of Neurology practice parameter identifies serum protein immunofixation electrophoresis as one of only three screening tests with the highest yield in evaluating distal symmetric polyneuropathy (DSP), alongside blood glucose and vitamin B12 with metabolites 1. This recommendation carries Level C evidence, meaning screening laboratory tests "may be considered" for all DSP patients, with these three tests specifically highlighted for their superior diagnostic performance.

In a Class III study of 279 consecutive patients with polyneuropathy of unknown etiology at a referral center, 10% had monoclonal gammopathy—a statistically significant increase over community prevalence 1. This finding has been consistently replicated, with recent studies confirming the ~10% prevalence 2, 3.

Critical Technical Consideration: Immunofixation Over Standard SPEP

A crucial pitfall: standard SPEP alone misses a substantial proportion of monoclonal proteins. The guidelines emphasize that serum protein immunofixation electrophoresis (IFE) is more sensitive than SPEP alone, especially for detecting small or non-malignant monoclonal gammopathies 1.

Specifically, in one study of 58 monoclonal gammopathies:

• 17% (10 of 58) were identified only by IFE and missed by SPEP
• For IgM paraproteins <5g/L, 30% (10 of 36) were detected only by IFE 1

This means ordering SPEP without immunofixation will miss nearly one in five paraproteinemic neuropathies.

The Misdiagnosis Problem

Recent data reveals the real-world consequences of inadequate screening. In a 2020 tertiary care study, 19% of patients with paraproteinemic neuropathy were initially misdiagnosed, either because they weren't screened for monoclonal protein or the paraprotein was incorrectly dismissed as benign MGUS 4. AL amyloidosis and POEMS syndrome were the most frequently missed diagnoses—both potentially fatal if untreated 4.

Even more concerning: 25% of neuropathy patients with monoclonal proteins had not undergone SPEP or IFE prior to referral, and free light chains (FLC) were not checked in any patients before referral 4. This represents a systematic gap in diagnostic evaluation.

Clinical Implications Beyond Detection

Distinguishing Causative from Coincidental Paraproteins

Not every monoclonal protein causes neuropathy—in the studies cited, only 44% of patients with both neuropathy and paraprotein had a causal relationship 4. The key is recognizing specific clinical phenotypes:

IgM paraproteins may indicate:

• Anti-MAG neuropathy (distal acquired demyelinating sensorimotor neuropathy/DADS)
• CANOMAD syndrome
• Type I or II cryoglobulinemia
• Waldenström macroglobulinemia 1, 2

IgG or IgA paraproteins may indicate:

• Multiple myeloma
• POEMS syndrome (especially with lambda light chains)
• Primary AL amyloidosis
• Chronic inflammatory conditions 1, 2

When to Escalate Testing

If SPEP with immunofixation is normal but clinical suspicion remains high (particularly with sensory and autonomic neuropathy), serum free light chains should be measured to screen for AL amyloidosis 2, 4. The 2020 study specifically recommends FLC testing when SPEP/IFE are normal in unexplained neuropathy 4.

Algorithmic Approach to Your Patient

For a patient with focal peripheral neuropathy presenting as toe pain:

1. Order SPEP with immunofixation (not SPEP alone) as part of the initial neuropathy workup 1, 5

2. If positive for monoclonal protein:

   • Determine immunoglobulin type and light chain
   • Collaborate with hematology/oncology to exclude plasma cell neoplasms or B-cell lymphomas 2
   • Consider bone marrow biopsy, skeletal survey, and additional testing based on paraprotein type
   • If lambda paraprotein with CIDP-like features: evaluate for POEMS syndrome 2, 4
   • If abnormal FLC ratio with sensory/autonomic features: evaluate for AL amyloidosis 2

3. If SPEP/IFE negative but high suspicion:

   • Order serum free light chains 2, 4
   • Consider urine immunofixation in select cases 2

4. Monitor for malignant transformation: Even "benign" MGUS can progress to malignancy over years, with risk factors including rising paraprotein titers and progressive neuropathy 6

The Bottom Line

Failure to order SPEP with immunofixation in unexplained peripheral neuropathy represents a missed opportunity to diagnose potentially treatable or life-threatening conditions. The test has one of the highest yields in neuropathy evaluation, and technical details matter—immunofixation must be included to avoid missing 17-30% of cases 1. Given that nearly 1 in 5 paraproteinemic neuropathies are initially misdiagnosed with devastating consequences 4, this test should be considered standard of care in the evaluation of unexplained peripheral neuropathy, including focal presentations like isolated toe pain that may represent early manifestations of length-dependent neuropathy 5.